Santhera Pharmaceuticals Holding AG (SPHDF) (H1 2026) Earnings Call Highlights: Revenue Doubles as AGAMREE Momentum Builds

As reported by gurufocus.com

Revenue: CHF48.3 million, up over 100% year-over-year, driven by strong AGAMREE sales and Nxera licensing income. CHF48.3 million, up over 100% year-over-year,...

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on gurufocus.com ↗

Market Samachar is a news aggregator. This article was originally published by gurufocus.com. Tap the button above to read the full story on their site.

INDIAN Bitcoin leads crypto market rebound above $85K as short liquidations accelerate Markets-Economic Times
INDIAN ETMarkets Smart Talk: Rupee under pressure, inflation sticky: Will RBI be forced to rethink rates? Ankita Pathak, Ionic Asset Markets-Economic Times
INDIAN Danish brewing giant Carlsberg’s India arm, 3 others get Sebi nod to float IPOs Markets-Economic Times
COMPANIES Coal India, NTPC among 360 ONE Capital Research’s 8 stock picks for October. Check full list with target prices Stocks-Markets-Economic Times
INDIAN ETMarkets Smart Talk| ‘Desi to Videsi’: How GIFT City is changing the way Indians invest globally — Mustafa Pardiwala Markets-Economic Times
GLOBAL US pressures Europe to release diesel reserves as Trump threatens export ban BBC News
CRYPTO Zano exploiter minted more than a quadrillion fUSD before blockchain rollback Cointelegraph.com News
INDIAN Kotak Mahindra Bank shares: How new MD-CEO Anup Saha's appointment can impact the stock - PL Capital decodes mint - markets

Santhera Pharmaceuticals Holding AG (SPHDF) (H1 2026) Earnings Call Highlights: Revenue Doubles as AGAMREE Momentum Builds

More from Market Samachar